Ken Eng

Genomics already has an important role in guiding therapeutic decision making. As we integrate genomic information of varying resolution, we’re learning much more about how tumors progress and what treatments will be effective for a given patient. This past year I have been focused on developing a platform for EXaCT-1 that is suitable for clinical enterprise use. What this means is we want all the work we’ve done in building the software that powers the analytics and report generation of EXaCT-1 to seamlessly integrate with existing systems at New York Presbyterian. As I look at the next year, we have an amazing opportunity to push all of our analytics to the cloud, a move that could expedite and enhance all our pipelines we’re developing to make clinical impact at a faster pace. I also look forward to working with the rest of the computational team and IPM to create an integrated solution where a physician would get tumor evolution predictions, drug/therapy recommendations, learn about newly published cancer research, and be able to interact with other physicians and researchers to create a collaborative mutli-disciplinary team armed with cutting-edge tools. Every patient should feel like they have the most qualified team of healthcare professionals helping them combat cancer.